Summary
- Oyster Point Pharma has filed to raise $85 million in an IPO, although the final figure may differ.
- The firm is advancing a pipeline of eye disease treatments.
- OYST has achieved very promising results in Phase 2b trials for its lead candidate and expects top-line readout for its Phase 3 trials by mid-2020.
- I'll provide an update when we learn IPO pricing and valuation information from management.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Oyster Point Pharma (OYST) has filed to raise gross proceeds of $85 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing treatments for ocular surface diseases.
OYST has produced very promising results in Phase 2b trials for its lead candidate for the treatment of dry eye disease.
Company & Technology
Princeton, New Jersey-based Oyster Point was founded in 2006 to develop new therapeutics for the treatment of eye diseases.
Management is headed by CEO and Director Jeffrey Nau, who has been with the firm since 2017 and was previously Vice President of Clinical and Medical Affairs at Ophthotech.
Below is a brief showcase video of the company’s technology:
